NCT06272864Recruiting
BostonGene and Exigent Genomic INsight Study
BostonGene and Exigent Genomic INsight (BEGIN) Study: A Prospective Study of Comprehensive Molecular Testing in Advanced Cancer Patients in the Community Setting
Source: ClinicalTrials.gov · Last updated 17 Feb 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The BEGIN Study by BostonGene and Exigent Genomic INsight evaluates the efficacy of comprehensive molecular testing in advanced cancer patients. Using the BostonGene Tumor Portrait test, the study aims to identify actionable findings, assess feasibility, and determine patient enrollment in clinical trials. Four cohorts of 100 patients each will be studied over two years, focusing on treatment decisions and patient outcomes. This study seeks to demonstrate the clinical utility of genomic testing in guiding therapy for advanced cancer patients in community settings.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 400 (estimated)
- First submitted
- 16 Feb 2024
- Start date
- 8 Apr 2024
- Primary completion date
- 8 Jan 2026
- Lead sponsor
- BostonGene
- Diseases
- Melanoma, Lung cancer, Sarcoma
- NCT number
- NCT06272864
What you commit to
- Study type: Observational
- Planned participants: 400
- From 8 Apr 2024 to the primary completion date, 8 Jan 2026
- 7 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- not meeting the inclusion criteria
Who the study is looking for
- Patients must have a confirmed malignancy of:
- Locally recurrent, unresectable, or metastatic breast cancer or; Unresectable stage III or metastatic non-small cell lung cancer or; Unresectable or metastatic melanoma or; Locally advanced or metastatic l sarcoma.
- Life expectancy \> 3 months as per the treating physician
- Willingness to provide informed consent
- Living in the United States at time of enrollment
- Agree to participate in genomic and molecular profiling
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (7)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| New Mexico Cancer Center Coordinator of this site? Confirm its status | Albuquerque | United States | Recruiting |
| Fort Wayne Medical Oncology and Hematology Coordinator of this site? Confirm its status | Fort Wayne | United States | Recruiting |
| Oncology Consultants Coordinator of this site? Confirm its status | Houston | United States | Recruiting |
| Northwest Medical Specialities Coordinator of this site? Confirm its status | Puyallup | United States | Recruiting |
| Highlands Oncology Group Coordinator of this site? Confirm its status | Rogers | United States | Recruiting |
| Stockton Hematology Oncology Medical Group Coordinator of this site? Confirm its status | Stockton | United States | Recruiting |
| Oklahoma Cancer Specialists and Research Institute Coordinator of this site? Confirm its status | Tulsa | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.